| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.27 | 4e-09 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.27 | 3e-07 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.16 | 7e-06 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-05 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.18 | 0.0002 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.18 | 0.0004 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0006 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.19 | 0.0009 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.17 | 0.001 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |